Liver

Latest Articles

Ursodeoxycholic Acid Treatment May Reduce the Risk of Preterm Birth

By

Bradley van Paridon

Researchers investigated whether treatment with ursodeoxycholic acid affected still birth and preterm birth in women with intrahepatic cholestasis of pregnancy.

Study Finds Liver Fibrosis to be an Independent Predictor of Diabetic Peripheral Neuropathy

By

Jessica Nye

Researchers evaluated the correlation of liver fibrosis and steatosis with diabetic peripheral neuropathy in patients with type 2 diabetes.

Disparities Found in Liver Cancer Surveillance Participation for Patients With Disabilities

By

Colby Stong

Investigators sought to determine disparities in liver cancer surveillance among patients with disabilities.

New Formulation of Hepatitis B Immune Globulin Launches

By

Steve Duffy

HyperHEP B is the Grifol’s new formulation of its hepatitis B immune globulin.

ACG Updates Guideline for Idiosyncratic Drug-Induced Liver Injury

The authors noted that DILI remains a diagnosis of exclusion based on a detailed history and use of blood tests, hepatobiliary imaging, and liver biopsy.

Lumasiran May Lower Urinary Oxalate Excretion in PH1

By

Colby Stong

Researchers investigated the efficacy of lumasiran in the reduction of hepatic oxalate production.

Atezolizumab Plus Bevacizumab Not Cost-Effective as First-Line Therapy for Unresectable or Metastatic HCC

By

Jessica Nye, PhD

Researchers compared the cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib for patients with unresectable or metastatic hepatocellular carcinoma.

FDA: Ocaliva Should Not Be Used in PBC Patients With Advanced Cirrhosis

By

Brian Park, PharmD

The FDA has identified 25 cases of serious liver injury leading to liver decompensation or liver failure associated with Ocaliva in PBC patients with compensated or decompensated cirrhosis.

Gut Dysbiosis May Be Alleviated After DAA Treatment for Hepatitis C Virus Infection

By

Sweta Gupta

Researchers assessed the influence of direct-acting antivirals on gut microbiota by analyzing microbial diversity and composition in patients with hepatitis C virus infection with or without HIV.

HBV Infection Not Linked to Liver Injury, Mortality in COVID-19

By

Kristin Della Volpe

Patients with current or past HBV infection are not at greater risk for liver injury or mortality during COVID-19 infection.

Risk Factors for Drug-Induced Liver Injury Identified in Hospitalized Patients

Drug-induced liver injury (DILI) has an incidence of 0.32 percent among hospitalized patients, and risk factors include hyperlipidemia, cardiovascular disease, preexisting liver disease, and surgical history.

SGLT2i and GLP-1RA May Improve NAFLD in T2DM

By

Vincent Soreca

Investigators examined the safety and efficacy of SGLT2i and GLP-1RA on treatment of nonalcoholic fatty liver disease in type 2 diabetes mellitus.

Serum Cardiac Biomarkers May Indicate Increased Risk for Severe CAD Among Patients With NAFLD

By

Jessica Nye, PhD

Researchers assessed cardiac biomarkers, among other clinical factors, associated with severe CAD in patients with NAFLD.

TDF Shows Long-Term Safety in Infants

By

Vincent Soreca

Investigators analyzed the safety of tenofovir disoproxil fumarate therapy during the third trimester of pregnancy.

PC Methods are Superior to EUS for LB

By

Virginia A. Schad, PharmD, RPh

Researchers conducted a randomized trial comparing specimen quality and financial costs between PC and EUS-guided liver biopsy methods.

Moderate-Intensity Aerobic Training and Resistance Training With Dietary Modification Equally Beneficial for NAFLD

By

Colby Stong

Investigators compared the effects of moderate-intensity aerobic vs resistance exercise with dietary modifications in patients with NAFLD.

Direct-Acting Antiviral Therapy and a Reduction in Extrahepatic Manifestations of HCV

By

Virginia A. Schad, PharmD, RPh

Researchers reviewed the effects of direct-acting antiviral therapies on the extrahepatic manifestations of HCV.

ABCC12 Gene in Chronic Cholestasis Syndromes

By

Joyce Lee

Researchers analyzed the genomes of children with chronic cholestasis for gene variants not typically associated with liver disease.

Once-Daily Semaglutide Shows Promise in Treating Severe Liver Disease

By

Jessica Nye

In this featured study from the New England Journal of Medicine, British researchers share the results of a phase 2 trial for semaglutide in 230 patients with NASH.

Current Options for the Diagnosis and Treatment of Pediatric Patients With Liver Tumors

By

Jessica Nye, PhD

While pediatric liver tumors remain rare, their diagnosis and treatment requires a systematic approach from a multi-professional team of clinicians.